舒洛地特联合贝那普利治疗糖尿病肾病临床观察

目的观察舒洛地特联合贝那普利治疗糖尿病肾病的临床疗效。方法选择糖尿病肾病患者45例,随机分为对照组22例和治疗组23例。对照组在常规治疗的基础上加用贝那普利,治疗组在对照组的基础上加用舒洛地特,8周后测定2组患者空腹血糖、24 h尿蛋白、纤维蛋白原(FIB)、尿β_2-微球蛋白(β_2-MG)、血清果糖胺,并比较分析。结果 2组FBG无明显变化,与治疗前比较,2组24 h尿蛋白均降低,FIB仅治疗组降低。与对照组比较,治疗组患者24 h尿蛋白、FIB、尿β_2-MG、果糖胺均降低(P<0.05,P<0.01)。结论舒洛地特联合贝那普利可更有效改善糖尿病肾病患者的肾功能。

Therapeutic effects of sulodexide combined with benazapril on patients with diabetic kidney disease

Objective To investigate the effects of combination therapy of sulodexide and benazapril in patients with diabetic kidney disease（DKD）.Methods Forty-five patients with DKD were randomly divided into control group（n =22） and treatment group（n = 23）.The control group was treated with benazapril,and the treatment group received the combination therapy of benazapril and sulodexide.After 8 weeks,fasting blood glucose（FBG）,24h urine protein,fibrinogen（FIB）, urineβ_2 -microglobulin（β_2-MG） and fructosamine were measured and compared between the two groups.Results The value of FBG didn＇ t changed obviously in the two groups.Compared with pre-treatment,the levels of 24h urine protein were decreased in both of the two groups.FIB was decreased only in treatment group.Compared with control group,the levels of 24h urine protein,FIB,β_2-MG and fructosamine were decreased in treatment group（P0.05,P0.01）.Conclusion Sulodexide combined with benazapril can improve renal function in patients with DKD.